CBG outperforms CBD for neuroprotection in Huntington's models; THCA protects dopaminergic neurons in Parkinson's models.
Neurodegenerative diseases — including Alzheimer's disease, Parkinson's disease, Huntington's disease, and ALS — are characterized by progressive neuronal loss. They affect 7+ million Americans and have limited disease-modifying treatments. The endocannabinoid system regulates neuroinflammation, oxidative stress, and neuronal survival — all central to neurodegeneration.
7+ million
Americans Affected
Alzheimer's: 6.7M; Parkinson's: 1M; Huntington's: 30,000
Prevalence
4
Key Studies
4
Cannabinoids Reviewed
Cannabinoids reduce neuroinflammation, oxidative stress, and excitotoxicity — the three primary drivers of neurodegeneration. CBG outperformed CBD for neuroprotection in Huntington's models. THCA protected dopaminergic neurons in Parkinson's models with greater potency than THC. Two independent labs (Salk Institute, University of Bonn) published CBG data for Alzheimer's in January 2026.
Microglial overactivation drives neuroinflammation in all major neurodegenerative diseases. CB2 receptor activation on microglia reduces pro-inflammatory cytokine release and microglial activation. CBD, CBG, and THCA all reduce neuroinflammation via CB2 and PPARγ.
Oxidative stress is a major driver of neuronal death in neurodegeneration. CBD and CBG are potent antioxidants — CBD's antioxidant activity is comparable to vitamins C and E. CBG reduced oxidative stress markers (lipid peroxidation, SOD activity) in Huntington's models.
CBG activated PPARγ in Alzheimer's models, upregulating ABCA1 — a cholesterol transporter that promotes amyloid-beta clearance. Two independent 2026 studies found CBG reduced amyloid-beta plaque burden by 41% in 5xFAD mice.
THCA protected dopaminergic neurons from MPTP toxicity in Parkinson's models via PPARγ activation — with greater potency than THC. Dopaminergic neuron loss is the defining pathology of Parkinson's disease.
Outperformed CBD for neuroprotection in Huntington's models. 41% amyloid-beta reduction in two independent 2026 Alzheimer's studies. Phase I Alzheimer's trial planned for late 2026.
More potent than THC for dopaminergic neuroprotection in MPTP model. Non-psychoactive. PPARγ mechanism.
Antioxidant, anti-inflammatory, and anti-apoptotic properties. Reduced neuroinflammation in long-COVID model (2026). Broad neuroprotective profile.
CBC promotes neural stem cell viability and differentiation into astrocytes — relevant to neuroregeneration. More effective than CBD for NSPC viability.
CBG Neuroprotection in Huntington's Disease Model
CBG improved motor deficits, reduced neuroinflammation and oxidative stress, outperforming CBD on several neuroprotection measures.
THCA Neuroprotection in Parkinson's Model
THCA protected dopaminergic neurons from MPTP toxicity with greater potency than THC via PPARγ activation.
CBG Reduces Amyloid-Beta in Alzheimer's Models
Two independent labs found CBG reduced amyloid-beta plaque burden by 41%, neuroinflammation by 38–44%, and improved cognition in Alzheimer's mouse models.
CBD Reduces Neuroinflammation in Long-COVID Model
CBD reduced microglial activation, neuroinflammatory cytokines, and cognitive deficits in long-COVID mouse model.
Dosing information is for educational purposes only. Always start with the lowest effective dose and consult a healthcare provider before use.
Start Dose
25mg CBD equivalent/day
Target Dose
100–300mg/day
Timing
Twice daily with food
All evidence is preclinical — no established human dosing. Full-spectrum preferred for entourage neuroprotective effects.